Monograph
N02AE01 - Buprenorphine |
Not porphyrinogenic |
NP |
Rationale
Substrate of CYP 3A4. Inhibitor os CYPs 3A4, 2D6, 1A1, 1A2, 2B6, 2C19, 2C8, 2C9, 2E1. Several references consider it safe. Significant clinical experience points to non-porphyrinogenicity.
Chemical description
Partial opioid antagonist used in postoperative pain and in Sweden also repeatedly in acute porphyric crises. Metabolized by CYP 3A4. MFM James, RJ Hift. Porphyrias. Br J Anaesth 2000; 85, 143-53: use EPI-list: safe Australian list: safe. South African list: use French list: use Without adverse reaction frequently used during acute porphyric crises (Sweden).
IPNet drug reports
Uneventful use reported in 6 patients with acute porphyria.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Serbia
